ephedrine has been researched along with Congenital Myasthenia in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Beeson, D; Ehrstedt, C; Frykholm, C; Liu, WW; Punga, AR | 1 |
| Argente-Escrig, H; Castañón, MJ; Clemen, CS; Herrmann, H; Kamm, L; Muelas, N; Schowalter, M; Schröder, R; Schultheis, D; Thiel, C; Türk, M; Vilchez, JJ; Wiche, G | 1 |
| Barros-Angueira, F; Eirís-Puñal, J; Fuentes-Pita, P; Gómez-Lado, C; López-Vázquez, A; Pardo, J; Pérez-Gay, L; Quintas-Rey, R | 1 |
| Eymard, B | 1 |
| Béhin, A; Eymard, B; Fardeau, M; Fournier, E; Hantaï, D; Laforêt, P; Nicole, S; Richard, P; Romero, N; Servais, L; Sternberg, D; Stojkovic, T | 1 |
| Beeson, D; Cossins, J; de Baets, M; Lashley, D; Liu, WW; Martinez-Martinez, P; Maxwell, S; Webster, RG; Wickens, JR | 1 |
| Scholten, RJ; van der Zwaag, AM; Verschuuren, JJ; Vrinten, C; Weinreich, SS | 1 |
| Beeson, D; Jayawant, S; Palace, J; Ramjattan, H; Robb, SA; Rodríguez Cruz, PM | 1 |
| Allen, D; Arunachalam, R; Beeson, D; Burke, G; Hammans, S | 1 |
| Abicht, A; Barisic, N; Deschauer, M; Lindberg, C; Lochmüller, H; Müller, JS; Schara, U; Straub, V; Strigl-Pill, N; Wendt, M | 1 |
| Lam, CW; Ng, PC; Yeung, WL | 1 |
| Beeson, D; Jayawant, S; Lashley, D; Palace, J; Robb, S | 1 |
| Abicht, A; Lochmüller, H; Mahjneh, I; Muntoni, F | 1 |
| Palace, J | 1 |
| Beeson, D; Burke, G; Cossins, J; Maxwell, S; Newsom-Davis, J; Nicolle, M; Palace, J; Robb, S; Vincent, A | 1 |
| Bestue-Cardiel, M; Capablo-Liesa, JL; Engel, AG; López-Pisón, J; Martin-Martinez, J; Peña-Segura, JL; Sáenz de Cabezón-Alvarez, A | 1 |
3 review(s) available for ephedrine and Congenital Myasthenia
| Article | Year |
|---|---|
[Congenital myasthenic syndromes: repurposing does not simplify access de facto - Clinical use of innovative, repurposed or off-label therapies: a real life experience (4)].
Topics: Albuterol; Cholinesterase Inhibitors; Drug Repositioning; Ephedrine; Health Services Accessibility; Humans; Myasthenic Syndromes, Congenital; Off-Label Use; Practice Patterns, Physicians'; Quality of Life; Quinidine; Therapies, Investigational; Treatment Outcome | 2019 |
[Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy--The French National Congenital Myasthenic Syndrome Network experience].
Topics: Adolescent; Adult; Central Nervous System Stimulants; Child; Delayed Diagnosis; Diagnostic Errors; Disease Progression; Ephedrine; Female; France; Humans; Information Centers; Male; Middle Aged; Myasthenic Syndromes, Congenital; Pregnancy; Prognosis; Young Adult | 2013 |
Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.
Topics: Adrenergic Agents; Adult; Child; Cholinesterase Inhibitors; Ephedrine; Humans; Infant, Newborn; Myasthenia Gravis; Myasthenia Gravis, Neonatal; Myasthenic Syndromes, Congenital | 2014 |
2 trial(s) available for ephedrine and Congenital Myasthenia
| Article | Year |
|---|---|
Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.
Topics: Cohort Studies; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Ephedrine; Follow-Up Studies; Genetic Predisposition to Disease; Genetic Testing; Humans; Muscle Proteins; Muscle Strength; Muscle, Skeletal; Mutation; Myasthenic Syndromes, Congenital; Outcome Assessment, Health Care; Patient Selection; Prospective Studies; Recovery of Function; Sympathomimetics; Treatment Outcome | 2010 |
Distinct phenotypes of congenital acetylcholine receptor deficiency.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Cell Line; Child; Child, Preschool; Cholinesterase Inhibitors; DNA Mutational Analysis; Drug Therapy, Combination; Electric Stimulation; Electromyography; Electrophysiology; Embryo, Mammalian; Ephedrine; Evoked Potentials, Motor; Female; Fluorescent Antibody Technique; Humans; Kidney; Male; Middle Aged; Muscle Proteins; Muscles; Mutation; Myasthenic Syndromes, Congenital; Phenotype; Potassium Channel Blockers; Protein Subunits; Pyridostigmine Bromide; Receptors, Cholinergic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Severity of Illness Index; Sympathomimetics; Transfection | 2004 |
11 other study(ies) available for ephedrine and Congenital Myasthenia
| Article | Year |
|---|---|
Novel pathogenic ALG2 mutation causing congenital myasthenic syndrome: A case report.
Topics: Albuterol; Electromyography; Ephedrine; Female; HEK293 Cells; Humans; Infant, Newborn; Muscle Proteins; Mutation; Myasthenic Syndromes, Congenital; Phenotype | 2022 |
Plectin-related scapuloperoneal myopathy with treatment-responsive myasthenic syndrome.
Topics: Adrenergic Agents; Adult; Ephedrine; Frameshift Mutation; Humans; Male; Muscular Dystrophy, Emery-Dreifuss; Myasthenic Syndromes, Congenital; Plectin | 2021 |
Clinical and neurophysiological response to ephedrine in a patient affected with slow-channel congenital myasthenic syndrome.
Topics: Alleles; Child; Electromyography; Ephedrine; Female; Heterozygote; Humans; Muscle Weakness; Mutation, Missense; Myasthenic Syndromes, Congenital; Phenotype; Point Mutation; Pyridostigmine Bromide; Receptors, Nicotinic | 2020 |
A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.
Topics: Adrenergic Agents; Animals; Disease Models, Animal; Ephedrine; Membrane Potentials; Mice; Mice, Transgenic; Miniature Postsynaptic Potentials; Mutation; Myasthenic Syndromes, Congenital; Neuromuscular Junction; Receptors, Cholinergic; Synaptic Transmission; Treatment Outcome | 2013 |
Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.
Topics: Adolescent; Adult; Albuterol; Cohort Studies; Drug Therapy, Combination; Ephedrine; Female; Humans; Male; Middle Aged; Myasthenic Syndromes, Congenital; Receptors, Cholinergic; Severity of Illness Index; Treatment Outcome | 2015 |
A treatable muscle disease.
Topics: Age Distribution; Aged; Disease Progression; Ephedrine; Extremities; Female; Gait Disorders, Neurologic; Genetic Predisposition to Disease; Horner Syndrome; Humans; Muscle Proteins; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Myasthenic Syndromes, Congenital; Neuromuscular Junction | 2009 |
Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations.
Topics: Adolescent; Adult; Child; Cohort Studies; Ephedrine; Face; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscle Proteins; Muscle Weakness; Mutation; Myasthenic Syndromes, Congenital; Prospective Studies; Severity of Illness Index; Sympathomimetics; Treatment Outcome | 2009 |
Intra-familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations.
Topics: Acetylcholinesterase; Adolescent; Asian People; Central Nervous System Stimulants; Collagen; Ephedrine; GPI-Linked Proteins; Heterozygote; Humans; Male; Muscle Proteins; Muscle Strength; Mutation; Myasthenic Syndromes, Congenital; Neural Conduction; RNA Splicing; Sympathomimetics; Time Factors; Treatment Outcome | 2010 |
DOK7 limb-girdle myasthenic syndrome mimicking congenital muscular dystrophy.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Diagnosis, Differential; Ephedrine; Female; Humans; Male; Middle Aged; Muscle Proteins; Muscle Strength; Muscle Weakness; Muscular Dystrophies, Limb-Girdle; Mutation; Myasthenic Syndromes, Congenital; Pakistan; Treatment Outcome | 2013 |
DOK7 congenital myasthenic syndrome.
Topics: Adolescent; Adult; Albuterol; Child; Child, Preschool; Diagnosis, Differential; Drug Therapy, Combination; Ephedrine; Humans; Infant; Infant, Newborn; Muscle Proteins; Myasthenic Syndromes, Congenital; Phenotype; Young Adult | 2012 |
Congenital endplate acetylcholinesterase deficiency responsive to ephedrine.
Topics: Acetylcholinesterase; Adolescent; Adrenergic Agents; Child; Cholinesterase Inhibitors; Diagnosis, Differential; DNA Mutational Analysis; Electromyography; Ephedrine; Female; Genetic Predisposition to Disease; Humans; Male; Muscle, Skeletal; Mutation; Myasthenic Syndromes, Congenital; Neostigmine; Neuromuscular Junction; Protein Structure, Tertiary; Synaptic Transmission | 2005 |